文献速递结核与非结核分枝杆菌艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV相关脓毒症的立即或高剂量抗结核治疗:ATLAS 3期随机对照试验

Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial.
PubMed 文献 · Lancet Infect Dis · 2026-01-28

ATLAS是在坦桑尼亚和乌干达四家医院开展的3期、开放标签、2×2析因、优效性随机对照试验,纳入437例HIV合并脓毒症成人,比较立即与诊断依赖抗结核治疗、高剂量与常规剂量抗结核治疗对28天死亡率的影响。结果显示,在全人群中立即治疗或高剂量治疗均未显著降低28天死亡率;

核心结论

  • 在全部HIV相关脓毒症参与者中,立即抗结核治疗或高剂量抗结核治疗均未显著降低28天死亡率。
  • 在后续确诊结核的亚组中,立即常规剂量抗结核治疗显著降低28天死亡率,提示尽早启动有效治疗可能影响生存。

研究设计与样本

  • ATLAS为3期、开放标签、随机对照、2×2析因、优效性试验,在坦桑尼亚和乌干达四家医院开展。
  • 筛查707人,随机分配437人至四组:立即常规剂量110例、立即高剂量112例、诊断依赖常规剂量107例、诊断依赖高剂量108例。
  • 395例接受干预并纳入主要结局分析,其中女性226例(57%)、男性169例(43%),全部为黑人。
  • 随机分配采用计算机生成的置换区组算法(区组大小4和8),按国家和随机化时精神状态分层,分配隐藏。

主要发现

  • 204例(52%)患者确诊结核。

关键数值与推荐

  • 入选标准:年龄≥18岁、HIV感染、因脓毒症入院且满足≥2项改良qSOFA标准。
  • 排除标准包括活动性结核或入院前6个月内接受抗结核治疗、妊娠或哺乳、抗结核药物过敏、慢性肝病、重型饮酒、血清隐球菌抗原阳性等。
  • 常规剂量组:利福平约10 mg/kg、异烟肼约5 mg/kg、吡嗪酰胺和乙胺丁醇按WHO推荐体重剂量,加吡哆醇50 mg口服。
  • 所有参与者每日接受头孢曲松2 g静脉注射共7天;立即治疗组持续抗结核治疗28天。

临床怎么用

  • 对于HIV合并脓毒症成人,不应仅凭经验常规启动立即抗结核治疗以降低短期死亡率。
  • 在高度怀疑或后续确诊结核的HIV脓毒症患者中,尽早启动常规剂量抗结核治疗可能改善生存。
  • 高剂量抗结核治疗未显示生存获益,且立即高剂量组药物性肝损伤事件数值上更多。

局限性

  • 主要结局在全人群未达显著,确诊结核亚组分析为探索性,需谨慎解读。
  • 试验为开放标签设计,可能影响不良事件判定或临床管理。
  • 研究对象全部为黑人,结果外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People living with HIV and hospitalised with sepsis in Africa are at risk of death due to tuberculosis but diagnostics for tuberculosis might be delayed or inaccessible for people presenting for critical care. We aimed to compare the effects of immediate empirical and high-dose antituberculosis therapy on 28-day mortality in adult people living with HIV with sepsis in east Africa. METHODS: ATLAS was a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial conducted at four hospitals in Tanzania and Uganda. Participants were aged 18 years or older, living with HIV, and had been admitted to hospital with sepsis with two or more modified quick Sequential Organ Failure Assessment score criteria. Exclusion criteria were active tuberculosis or receipt of antituberculosis therapy within 6 months of hospitalisation, pregnancy or lactation, allergies to antituberculosis therapy, another investigational drug within the past month, chronic liver disease, heavy alcohol use, positive serum cryptococcal antigen, or anticipated significant drug-drug interaction with rifampicin. A computer-generated permuted-block algorithm with allocation concealment and random block sizes of four and eight randomly assigned participants (1:1) to receive either immediate or diagnosis-dependent antituberculosis therapy, and (1:1) to receive either high-dose or conventional WHO-recommended weight-based dose antituberculosis therapy. Allocation was stratified by country and the presence of altered mental status at the time of randomisation. Participants randomly assigned to conventional-dose antituberculosis therapy received fixed-dose combination tablets of rifampicin approximately 10 mg/kg, isoniazid approximately 5 mg/kg, pyrazinamide, and ethambutol, plus pyridoxine 50 mg orally. Participants randomly assigned to receive high-dose antituberculosis therapy received rifampicin approximately 30 mg/kg and isoniazid approximately 7·5 mg/kg as a combination of single formulation tablets and fixed-dose combination tablets that included WHO-recommended weight-based doses of pyrazinamide and ethambutol, plus pyridoxine. Participants continued immediate antituberculosis therapy for 28 days. All medications were administered daily. Participants in the diagnosis-dependent antituberculosis therapy groups received treatment based on a clinical or microbiological diagnosis of tuberculosis. All participants received 2 g intravenous ceftriaxone daily for 7 days. The primary endpoint was 28-day mortality analysed in the modified intention-to-treat population and in the subgroup with later confirmed tuberculosis. We defined the survival time for each participant as the time from randomisation until death, discharged (alive) by day 28, or censored (alive) at day 28. We graded adverse events according to recommendations from the National Institutes of Health Division of AIDS. This study was registered with ClinicalTrials.gov, NCT04618198, and is completed. FINDINGS: Between Jan 5, 2022, and Dec 9, 2024, 707 people were screened for eligibility and 437 were randomly assigned (110 to immediate conventional-dose, 112 to immediate high-dose, 107 to diagnosis-dependent conventional-dose, and 108 to diagnosis-dependent high-dose antituberculosis therapy). 395 patients (226 [57%] of whom were female and 169 [43%] were male; all participants were Black) received study intervention and were analysed for the primary outcome of 28-day mortality. We confirmed tuberculosis in 204 (52%) patients. There was no evidence of differences in 28-day mortality in immediate antituberculosis therapy groups (50 deaths [25%] in 198 patients) compared with diagnosis-dependent groups (50 deaths [25%] in 197 patients; adjusted hazard ratio [aHR] 0·99 [95% CI 0·67-1·46]; p=0·95), or in high-dose antituberculosis therapy groups (51 deaths [26%] in 199 patients) compared with conventional-dose groups (49 deaths [25%] in 196 patients; aHR 1·07 [0·72-1·59]; p=0·73). In patients with microbiologically confirmed tuberculosis, the 28-day mortality relative to the diagnosis-dependent conventional-dose group (18 deaths [34%] in 53 patients) was lower for the immediate conventional-dose group (six deaths [12%] in 51 participants; aHR 0·32 [95% CI 0·13-0·82]; p=0·015); for the diagnosis-dependent high-dose group (11 deaths [20%] in 56 patients) was 0·51 (0·24-1·08; p=0·079); and for the immediate high-dose group (11 deaths [26%] in 43 patients) was 0·63 (0·29-1·36; p=0·24). No significant differences in adverse events occurred between treatment groups but numerically more events of drug-induced liver injury occurred in the immediate high-dose group compared with any other group. INTERPRETATION: Among all participants with HIV-related sepsis, 28-day mortality was not significantly reduced with immediate or high-dose antituberculosis therapy. In the subgroup with later confirmed tuberculosis, immediate conventional-dose antituberculosis therapy significantly reduced 28-day mortality, suggesting, as in other forms of bacterial sepsis, that hours to active treatment might determine survival. FUNDING: US National Institutes of Health.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Heysell SK, Mpagama SG, Nuwagira E, et al. Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial. Lancet Infect Dis. 2026. PMID: 41619753. doi:10.1016/S1473-3099(25)00747-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。